Guest Column

Panel featuring Houston innovator discusses rapidly changing innovation ecosystem

The panel at the inaugural conference featured Brad Rossacci of Accenture Innovation. Courtesy of INNO

Recently, Brad Rossacci, Accenture's Houston Innovation Hub's disruptive innovationeer and creative director, participated in the inaugural INNO, a conference dedicated to supporting the community of innovators, collaborators, and industry disruptors by providing them with a forum to share knowledge, connect with colleagues from around the world, and identify opportunities to work together.

Brad made the trip to New Orleans not just to speak, but also to see first-hand how Houston's neighboring cities are approaching the ideas, themes, and business best practices he's developing within Accenture and more broadly, within the Houston business community.

Speaking as part of the kickoff keynote, titled "What Corporate Innovators Seek," Brad was joined on stage by Aimee Quirk of InnovationOchsner, Lauren Kenney, vice president of Grid Modernization and Strategy at Entergy, and panel facilitator Chase Langdon, Partnership Strategy Manager for the New Orleans Saints and Pelicans. Seated on the INNO stage, Brad had the ideal spot to both share his own expertise, and to hear first hand about how big businesses are working with startups and entrepreneurs outside of Houston.

During the course of the discussion it became clear that all the panelists and the organizations they represent are on the same page in several important ways: all of these companies have big footprints within their local communities and beyond. All have concluded that the challenges facing their different industries and economic sectors — as well as their organizations specifically— require a broader set of skills, backgrounds, and expertise to work through than can be found within the walls of any single company. And all have come to appreciate that to remain a business leader in an increasingly agile and rapidly transforming world, the work of innovation and problem solving must be approached with intentionality and given enough freedom to move fast enough to keep up and get ahead.

They also differ in key respects. The companies represented did not all arrive at these conclusions at the same time. Accordingly, their innovation initiatives are at different stages of development and implementation, both with regard to putting together internal innovation- focused teams and in finding outside companies to partner and collaborate with. Moreover, there are challenges specific to their industries that impact how they pursue their innovation goals. They also face different challenges in terms of getting support from the rest of their organizations. Nevertheless, there have been some challenges that all panelists experienced in some capacity, as well as some agreed-upon best practices.

All agreed that when hiring for internal innovation teams or initiatives, the primary qualification is not a specific set of skills or work history, but rather a specific mindset: they are looking for creative problem solvers who are willing to think and do things differently and who are not intimidated by challenges. Another point they all agreed on is that it's not always easy to find these innovation-oriented people, and that it can be difficult to entice them away from other markets. In particular, the New Orleans based businesses represented expressed feeling the pinch of a limited talent pool.

As the conversation facilitator, Chase Langdon was informed by some of the goals and challenges he's facing as Partnership Strategy Manager for the New Orleans Saints and Pelicans. Reflecting on the structure of the discussion, shared that his team is increasingly cognizant of the potential they have to make an impact on the business community within the region by nurturing holistic economic growth. The Saints and the Pelicans are among the most visible and recognizable local business entities, and his team is actively exploring ways to leverage that visibility to drive growth through partnerships.

Accordingly, his questions reflected an interest in learning from the other organizations represented.

So what are some of the key take away points that Chase and other attendees interested in launching their own innovation initiatives, or in partnering with other organizations? Aimee noted that for those looking to do business with companies like Ocshner, it's important to think about what it takes to be a good partner, not just what it takes to get the deal done. There was general agreement that one of the advantages to working with startups is that they can move quickly as they are less burdened by legacy processes of an older institution.

Similarly, innovators and problem solvers, whether part of internal teams or outside partners, need to be empowered and supported when taking the risks inherent in exploration and experimentation. Brad, in particular, noted that he considers creating an environment that nurtures and protects the "beautiful minds" of his team and the larger Houston innovation ecosystem, to be one of the primary responsibilities of his job.

"Startups are the rockstars now," he says, and existing companies looking to remain competitive need to take a hands-on approach to cultivating a collaborative and sustainable business environment with the required diversity of experiences, perspectives, and skills that lead to breakthroughs.

------

Lizy Freudmann is head of marketing for the INNO.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted